登录

Pelago宣布提供5800万美元的C系列资金,以加强在药物使用管理方面的领导地位

Pelago Announces $58 Million Series C Funding to Strengthen Leadership in Substance Use Management

Healthcare IT Today | 2024-05-02 | 翻译由动脉网AI生成,点击反馈

可切换为仅中文


Investment Follows Strong Employer and Health Plan Demand as Substance Use Management Moves from Niche Solution to Essential Benefit Resulting in 287% Revenue Growth in 2023 and 100% Client Retention

随着物质使用管理从利基解决方案转向基本利益,投资紧随雇主和健康计划的强劲需求,2023年收入增长287%,客户保留率达到100%

Growth Follows 500% Increase in Substance Use Disorder-Specific RFPs from Employers and Payers in the Past Twelve Months

在过去的十二个月中,来自雇主和付款人的针对物质使用障碍的RFP增加了500%,随后出现了增长

Platform Covers More than 3.4 Million Eligible Lives

该平台覆盖了340多万个符合条件的生命

Pelago, the leading digital clinic partner to U.S. businesses and health plans for substance use management, today announced $58 million in new funding on the strength of customer growth and validated ROI, bringing total funding to $151 million.

Pelago是美国商业和健康计划物质使用管理的领先数字诊所合作伙伴,今天宣布了5800万美元的新资金,这是基于客户增长和有效的投资回报率,使总资金达到1.51亿美元。

The additional capital raised will help Pelago accelerate its product roadmap, extend its continuum of care, and advance clinical research efforts. Existing investor Atomico doubled down to lead this Series C investment on the back of Pelago’s impressive growth, with participation from all existing investors Kinnevik AB, Octopus Ventures, and Y Combinator plus new investors Eight Roads and GreyMatter Capital.

筹集的额外资金将有助于Pelago加快其产品路线图,扩展其连续护理,并推进临床研究工作。现有投资者Atomico加倍努力,在Pelago令人印象深刻的增长背后领导这项C系列投资,所有现有投资者Kinnevik AB、Octopus Ventures和Y Combinator加上新投资者Eight Roads和GreyMatter Capital都参与了这项投资。

As part of this latest round, Atomico Partner Laura Connell will join the Pelago board..

作为最新一轮的一部分,Atomico合伙人劳拉·康奈尔(LauraConnell)将加入Pelago董事会。。

“I’m so proud of the work we have done to improve lives and expand access to substance use care that works. We empower employers and payers to bring our solution to their members struggling with tobacco, alcohol, or opioids, from prevention to treatment and recovery,” said Pelago CEO and Co-Founder Yusuf Sherwani, M.D.

Pelago首席执行官兼联合创始人Yusuf Sherwani医学博士说:“我为我们为改善生活和扩大药物使用护理所做的工作感到骄傲。我们授权雇主和付款人为他们的成员提供解决方案,从预防到治疗和康复,他们都在与烟草、酒精或阿片类药物作斗争。”。

“We’re addressing a gap in the market left by employee assistance programs and mental health benefits providers who are unable to detect and treat substance use disorders. Customers are resonating with our solution as evidenced by a tenfold growth in revenue and eligible lives since our Series B two years ago.”.

“我们正在解决无法发现和治疗药物使用障碍的员工援助计划和心理健康福利提供者在市场上留下的差距。客户对我们的解决方案产生了共鸣,自两年前的B系列以来,收入和合格生活增长了十倍。”。

Pelago was founded on the premise that substance use is a treatable chronic condition. The company is addressing the rising rates and costs of substance misuse head-on through its 100 percent fees-at-risk model that delivers improved outcomes and demonstrated ROI. In the industry’s first-ever substance use management medical claims analysis, Pelago’s substance use management program reduced medical claims on an annual basis by $9,367 per participant compared to a control group, delivering a 3.0x ROI.

Pelago是建立在物质使用是一种可治疗的慢性病的前提下的。该公司正通过其100%风险收费模型正面应对药物滥用率和成本的不断上升,该模型提供了改进的结果和显示的投资回报率。在业界首次进行的物质使用管理医疗索赔分析中,与对照组相比,Pelago的物质使用管理计划每年将每位参与者的医疗索赔减少9367美元,投资回报率为3.0倍。

More than 80 percent of cost savings realized in the Pelago analysis were attributable to lower medical spend, with the remainder tied to lower behavioral health costs..

在Pelago分析中实现的80%以上的成本节约归因于医疗支出的减少,其余部分与行为健康成本的降低有关。。

“Yusuf and the Pelago team are building the category-defining company in substance use management and in doing so, addressing one of this generation’s most urgent healthcare needs,” said Connell. “Their visionary leadership in the substance use management space, in offering treatment as an employee benefit to the world’s most forward-thinking companies, is reflected in their exceptional growth, a testament to the significant and rapidly growing demand for better solutions.

康奈尔说:“优素福(Yusuf)和佩拉戈(Pelago)团队正在建立一家物质使用管理领域的类别界定公司,并以此来满足这一代人最迫切的医疗保健需求之一。”。“他们在物质使用管理领域具有远见卓识的领导地位,为世界上最具前瞻性思维的公司提供员工福利待遇,这反映在他们的非凡增长中,这证明了对更好解决方案的巨大且快速增长的需求。

Pelago’s ability to expand and accelerate access to best-in-class substance use care results in a major improvement in clinical outcomes and costs with clear and material ROI for employers. Atomico is incredibly proud to have supported the Pelago team on the journey thus far and to be doubling down on our partnership now.”.

Pelago能够扩大和加速获得一流的物质使用护理,从而大大改善了临床结果和成本,为雇主带来了明确而实质的投资回报率。到目前为止,Atomico非常骄傲地支持了Pelago团队的旅程,现在我们的合作伙伴关系将加倍。”。

With rapidly rising healthcare costs, employers and health plans are laser-focused on value, cost-savings, and performance-based care for their employee and member benefits. According to recent surveys from consulting firms Mercer and WTW, costs for workplace health plans in 2024 will jump more than 6 percent.

随着医疗保健成本的快速上升,雇主和健康计划都将重点放在价值、成本节约以及基于绩效的员工和会员福利护理上。根据咨询公司Mercer和WTW最近的调查,2024年工作场所健康计划的成本将增加6%以上。

Moreover, recent Centers for Disease Control and Prevention research has reported the annual minimum direct cost of substance use disorders (SUDs) at $15,640 per affected employee enrolled in employer-sponsored insurance, totaling more than $35 billion annually..

此外,最近的疾病控制和预防研究中心报告称,参加雇主赞助保险的每位受影响员工每年的物质使用障碍(SUD)最低直接费用为15640美元,每年总计超过350亿美元。。

In non-specialized SUD treatment settings, research shows up to 89% of adults with SUDs may go undetected, resulting in delays in treatment, relapse, and increased costs. And for those that do receive SUD treatment in mental health settings – the treatment itself is not the specialized SUD treatment they need.

在非专业的SUD治疗环境中,研究表明,高达89%的成人SUD可能未被发现,导致治疗延迟,复发和成本增加。对于那些在心理健康环境中接受SUD治疗的人来说,治疗本身并不是他们所需要的专门的SUD治疗。

All the while, the consequences in terms of hidden financial and productivity impacts remain buried in medical claims and absenteeism, dramatically impacting a company’s bottom line in the form of costly health problems, inpatient and outpatient care, poor utilization management, and lower productivity..

一直以来,隐藏的财务和生产力影响的后果仍然隐藏在医疗索赔和缺勤中,以昂贵的健康问题、住院和门诊护理、利用管理不善和生产力低下的形式极大地影响了公司的底线。。

“As a company that provides our employees with a broad range of health, life, and voluntary benefits, Live Nation Entertainment is proud to offer Pelago’s value-based, substance use management benefit,” said Emily Munroe, Director, Benefits for Live Nation Entertainment. “I congratulate Pelago on its funding raise, and I look forward to a continued strong relationship with their entire team.”.

Live Nation Entertainment福利总监艾米丽·门罗(Emily Munroe)表示:“作为一家为员工提供广泛的健康、生活和自愿福利的公司,Live Nation Entertainment很自豪能够提供Pelago基于价值的物质使用管理福利。”。“我祝贺Pelago筹集资金,我期待着与他们的整个团队继续保持牢固的关系。”。

Pelago offers integrated substance use management to employer and health plan populations, with specialized treatment for tobacco, alcohol, and opioid use disorders along with support for adolescents. For more information, visit pelagohealth.com.

Pelago为雇主和健康计划人群提供综合物质使用管理,专门治疗烟草,酒精和阿片类药物使用障碍,并支持青少年。有关更多信息,请访问pelagohealth.com。

About Pelago

关于Pelago

Pelago partners with enterprises as the leading virtual clinic for substance use management among their employees. We are transforming substance use support – from prevention to treatment – delivering education, management skills, and opportunities for positive change to members struggling with substance use, most commonly tobacco, alcohol, or opioids.

Pelago与企业合作,成为其员工物质使用管理的领先虚拟诊所。我们正在将物质使用支持从预防转变为治疗,为正在与物质使用(最常见的是烟草、酒精或阿片类药物)作斗争的成员提供教育、管理技能和积极改变的机会。

Our solution gives employers the means to offer on-demand, personalized support to workers seeking to live healthier lives. Pelago’s cognitive behavioral therapy (CBT) and medication-assisted treatment (MAT) programs deliver convenient, accessible, and effective support that seamlessly integrates with health plans, pharmacy benefit managers, and wellness platforms.

我们的解决方案使雇主能够为寻求更健康生活的工人提供按需、个性化的支持。Pelago的认知行为疗法(CBT)和药物辅助治疗(MAT)计划提供方便,可访问和有效的支持,与健康计划,药房福利管理人员和健康平台无缝集成。

Tens of thousands of members enroll in the Pelago program each year, and more than 3.4 million now have access to the digital clinic..

每年有数以万计的成员加入Pelago计划,现在有340多万人可以使用数字诊所。。

Originally announced March 28th, 2024

最初于2024年3月28日宣布

TagsAtomico Eight Roads Emily Munroe Greymatter Capital Health IT Funding Health IT Fundings Health IT Investment Kinnevik AB Laura Connell Live Nation Entertainment Octopus Ventures Pelago Y Combinator Yusuf Sherwani

TagsAtomico八路Emily Munroe Greymatter Capital Health IT Funding Health IT Fundings Health IT Investment Kinnevik AB Laura Connell Live Nation Entertainment Octopus Ventures Pelago Y Combinator Yusuf Sherwani

Get Fresh Healthcare & IT Stories Delivered Daily

每天提供新鲜的医疗保健和IT故事

Join thousands of your healthcare & HealthIT peers who subscribe to our daily newsletter.

加入成千上万订阅我们每日新闻稿的healthcare&HealthIT同行。

We respect your privacy and will never sell or give out your contact information

我们尊重您的隐私,绝不出售或泄露您的联系信息

推荐阅读

Pelago推出大麻使用障碍治疗计划

businesswire 2024-04-23 19:00

Pelago宣布启动应急管理计划

businesswire 2024-04-09 19:00

2024年3月全球医疗健康领域投融资月报

动脉网APP 2024-04-03 18:39

Healthcare IT Today

128篇

最近内容 查看更多

医疗软件解决方案提供商DrFirst完成收购Myndshft Technologies,通过兼顾药房和医疗效益,彻底改变药物管理

14 小时前

住院之旅分析服务提供商Kontakt.io从筹集4750万美元融资,推动人工智能开发和向美国医院扩张

3 天前

Change Healthcare勒索软件攻击会唤醒Healthcare吗?

2024-05-13

相关公司查看更多

Pelago

数字诊所服务提供商

立即沟通

产业链接查看更多

所属赛道

专科医院与诊所
数字疗法
近30天,融资4起
动脉橙产业智库梳理了:近10年数字疗法相关政策100+;发布时间、实施地区、政策内容等等分析维度,并将持续更新。
商业保险